Viela Bio, Inc.
Viela Bio, Inc. (VIE): 5 pipeline candidates · ~129 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
128.5 months
D/E 0.13 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Viela Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$130.1M
Quarterly Burn
$8.5M
Runway
128.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| inebilizumab | Phase 2 |
| uplizna | Approved |
| vib1116 | Preclinical |
| vib4920 | Phase 2 |
| vib7734 | Phase 1 |
Frequently asked questions
How many drug candidates are in Viela Bio, Inc.'s pipeline?
Viela Bio, Inc. (VIE) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Viela Bio, Inc.'s lead drug candidate?
Viela Bio, Inc.'s most advanced tracked candidate is inebilizumab (Phase 2) for IgG4-related disease.
What is Viela Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Viela Bio, Inc. has approximately 128.5 months of cash runway.
Who is the CEO of Viela Bio, Inc.?
One Med is the chief executive officer of Viela Bio, Inc. (VIE).
Get the full picture on Viela Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.